Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2021

View Archived Issues

Janssen describes new dihydroorotate dehydrogenase inhibitors

New CDK7 inhibitors discovered at Lilly

Senda Biosciences identifies aryl hydrocarbon receptor antagonists

New three-prime repair exonuclease 1 inhibitors synthesized at Constellation Pharmaceuticals

Axial Therapeutics discovers Toll-like receptor 2 agonists

REST loss promotes breast cancer tumor progression

AcuraStem presents preclinical data for AS-202 in ALS

Novel CD70-directed CAR-NK cells for the treatment of CD70-positive malignancies

Researchers discover more than 1,300 genes linked to congenital heart disease

PFKFB3 targeting shows promise for treating breast cancer

DAN-311 demonstrates consistent and durable efficacy in HER2-low breast cancer models

SRSF1 is a therapeutic target for the treatment of breast cancer

Discovery of T-036, a novel brain-penetrant GCS inhibitor for the treatment of Gaucher's disease

Celularity and Sorrento Therapeutics present preclinical data for CAR19-CYNK immunotherapeutic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...